Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Next Previous
Trial Profile

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Adrenocortical carcinoma; Advanced breast cancer; Appendiceal cancer; Basal cell cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Chordoma; Choriocarcinoma; Colon cancer; Colorectal cancer; Endometrial cancer; Extramammary Paget disease; Fibroma; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Gestational trophoblastic disease; Giant cell tumours; Haemangiosarcoma; Head and neck cancer; Laryngeal cancer; Lung cancer; Nerve sheath neoplasms; Neuroblastoma; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Paraganglioma; Parathyroid cancer; Pelvic cancer; Peritoneal cancer; Perivascular epithelioid cell tumours; Phaeochromocytoma; Pharyngeal neoplasms; Pituitary cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Seminoma; Solid tumours; Squamous cell cancer; Teratoma; Thyroid cancer; Tracheobronchial cancer; Trophoblastic tumour; Urogenital cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Acronyms DART

    • Most Recent Events

    • 13 Dec 2023 Planned End Date changed from 31 Oct 2024 to 1 May 2026.
    • 13 Dec 2023 Planned primary completion date changed from 31 Oct 2024 to 1 May 2026.
    • 26 Oct 2023 Results (n=4) of the GTN cohort 47 assessing efficacy of Ipilimumab plus nivolumab in chemotherapy-refractory GTN, published in the Clinical Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top